BP-100-1.01 (Liposomal Grb-2), the lead anti- leukemic product of Bio-Path Holdings Inc. that has shown efficacy and effectiveness in the management of refractory blood cancers like myelodysplastic disorder, acute myelocytic leukemia and recurrent blood cancers, will now be tested for the management and treatment of inflammatory breast cancer (IBC) and triple negative breast cancer (TNBC), as announced by the representatives of the company.
The overall prognosis of IBC and TNBC is worse, and so far there is no treatment protocol for either, leading to a high mortality rate due to the extensive and aggressive disease. Liposomal Grb-2 employs anti-sense technology for the delivery of liposomal units within the cancer cells that selectively inhibit cancer proteins without affecting the integrity of entire cell.
The CEO of Bio-Path Holdings, Peter Neilson suggests:
“Several attempts have been made to develop antisense technology, but these results have produced toxicity and poor uptake into diseased cells. Bio-Path’s technology is unique because it creates no toxicity and has widespread uptake into target cells. This is a game changing story that can change the way that cancer is being treated.”
The clinical trials conducted at MD Anderson, Texas suggest a potential anti-leukemic action of the liposomal delivery system, and it is expected that the similar quality of results will be obtained from the trials conducted on breast cancer patients. Neilson believes that the company provides a huge investment opportunity with a promising chance of smart and steady growth for investors. With a current market potential of $4+ billion, it is also expected that the liposomal delivery system can also offer applications outside the cancer treatment.
Certified Financial Analyst, Grant Zeng suggests in his post on Zacks.com that the current stock situation of Bio-Path Holdings is encouraging from an investment point of view. He wrote:
“By comparing it to its peers in the biotech industry and considering the potential of its drug delivery technology and progresses the company has made in the past few months, we think Bio-Path’s stock should be trading around $1.00 per share, which values the Company at about $62 million in market cap”
Liposomal Grb- 2 and liposomal delivery technology will also be utilized for the preparation and development of other drugs and pharmacological preparations for a variety of diseases in coming years.